DURECT to Present at the BTIG Biotechnology Conference 2020

On August 5, 2020 DURECT Corporation (Nasdaq: DRRX) reported that James E. Brown, President and CEO, Michael H. Arenberg, Chief Financial Officer and Dr. WeiQi Lin, Executive Vice President of R&D will be participating in a fireside chat at the BTIG Biotechnology Conference 2020, Monday, August 10, 2020 at 11:00 a.m. EDT / 8:00 a.m. PDT. Institutional investors that are participating in the conference may request a virtual one-on-one meeting through the conference coordinators (Press release, DURECT, AUG 5, 2020, https://investors.durect.com/news-releases/news-release-details/durect-present-btig-biotechnology-conference-2020?field_nir_news_date_value[min]=2020 [SID1234562944]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

A live audio webcast of the presentation will be available by accessing
View Source

The live audio webcast of the presentation will also be available by accessing DURECT’s homepage at www.durect.com and clicking on the "Investors" tab. If you are unable to participate during the live webcast, the call will be archived on DURECT’s website in the "Event Calendar" of the "Investors" section.

The China Center for Drug Evaluation, National Medical Products Administration Has Recommended Breakthrough Therapy Designation for ciltacabtagene autoleucel (cilta-cel, LCAR-B38M CAR-T Cells), an Investigational BCMA CAR-T Cell Therapy

On August 5, 2020 Legend Biotech Corporation (NASDAQ:LEGN) reported that the China Center for Drug Evaluation, National Medical Products Administration (CDE, NMPA) has recommended Breakthrough Therapy Designation (BTD) for ciltacabtagene autoleucel (cilta-cel; LCAR-B38M CAR-T cells), an investigational B-cell maturation antigen (BCMA) targeted chimeric antigen receptor (CAR) T-cell therapy being studied for the treatment of adults with relapsed or refractory multiple myeloma (RRMM) (Press release, Legend Biotech, AUG 5, 2020, View Source [SID1234562960]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The BTD for cilta-cel (LCAR-B38M CAR-T cells) is based on the ongoing Phase 2 CARTIFAN-1 study being conducted in China (MMY2002, NCT03758417, CTR20181007), the ongoing Phase 1b/2 CARTITUDE-1 study of cilta-cel (JNJ-4528) being conducted in the US (MMY2001, NCT03548207) and Japan and the Phase 1, first-in-human LEGEND-2 study conducted in China (NCT03090659). Ciltacabtagene autoleucel (cilta-cel) refers to both LCAR-B38M CAR-T cells and JNJ-4528. LCAR-B38M CAR-T cell identifies the investigational product being studied in China and JNJ-4528 identifies the investigational product being studied outside of China, both of which are representative of the same CAR-T cell therapy.

The BTD procedure is part of the recently revised Drug Registration Regulation which went into effect on July 1, 2020. The BTD process is designed to expedite the development and review of therapies that are intended for treatment of serious diseases for which there is no existing treatment and where preliminary evidence indicates advantages of the therapy over available treatment options.1 Cilta-cel is the first product that has been recommended for BTD in China.2 As per the working procedure for BTD (2020 No.82) issued by NMPA on July 8, 2020, CDE had completed the review and recommended to grant the BTD on August 4th, and BTD will be granted after 5 working days of publicity period (August 5 to 12) on the CDE website.

In December 2017, Legend Biotech entered into a worldwide collaboration and license agreement with Janssen Biotech, Inc., one of the Janssen Pharmaceutical Companies of Johnson & Johnson, to jointly develop and commercialize cilta-cel in patients with multiple myeloma. Cilta-cel is a structurally differentiated CAR-T cell therapy containing a 4-1BB co-stimulatory domain and two BCMA-targeting single domain antibodies designed to confer avidity.

"Breakthrough designation recommendation by the China CDE of NMPA represents an important regulatory milestone in the continued development of cilta-cel in multiple myeloma patients in China," said Frank Zhang, PhD, CEO of Legend Biotech. "Legend, in collaboration with Janssen, will continue to advance this investigational therapy in China and globally."

Previously, the following regulatory designations have been granted to Janssen for cilta-cel:

In July 2020, the Korea Ministry of Food and Drug Safety granted orphan drug designation.3
In June 2020, the Japan Ministry of Health, Labor and Welfare granted orphan drug designation.4
In February 2020, the European Commission granted orphan designation.5
In December 2019, the U.S. Food and Drug Administration (FDA) granted Breakthrough Therapy Designation.6
In April 2019, the European Medicines Agency granted Janssen a PRIME (PRIority MEdicines) designation.7
In February 2019, the FDA granted Janssen orphan drug designation for the treatment of multiple myeloma.8
About the Clinical Development Program

CARTIFAN-1
The Phase 2 CARTIFAN-1 confirmatory trial (MMY2002, NCT03758417, CTR20181007) is being conducted in China to further evaluate cilta-cel (LCAR-B38M CAR-T cells) in patients with RRMM who have received at least 3 prior lines of therapy and have received a proteasome inhibitor (PI) and an immunomodulatory drug (IMiD); and documented disease progression within 12 months of starting the most recent therapy. 9

CARTITUDE-1
Cilta-cel (JNJ-4528) is currently being investigated in the Phase 1b/2 CARTITUDE-1 (MMY2001, NCT03548207) pivotal study conducted in US and Japan for the treatment of patients with multiple myeloma who have received at least 3 prior lines of therapy or are double refractory to a PI and IMiD; received a PI, an IMiD and anti-CD38 antibody; and documented disease progression within 12 months of starting the most recent therapy. 10

CARTITUDE-2
The global, multi-cohort Phase 2 CARTITUDE-2 (MMY2003, NCT04133636) study, cilta-cel (JNJ-4528) is actively recruiting patients with multiple myeloma in various clinical settings. This study is being conducted to evaluate the overall minimal residual disease (MRD) negative rate of participants who receive JNJ-4528 to further explore efficacy and safety in earlier patient populations.11

CARTITUDE-4
The global, Phase 3 CARTITUDE-4 (MMY3002, NCT04181827) study, cilta-cel (JNJ-4528) is actively recruiting patients with multiple myeloma who have received 1-3 prior lines of therapy including a PI and IMiD and are refractory to lenalidomide. The study is being conducted to evaluate the efficacy of JNJ-4528 compared to standard therapies7 including daratumumab, pomalidomide and low-dose dexamethasone (DPd) or pomalidomide, bortezomib and low-dose dexamethasone (PVd).12

LEGEND-2
LEGEND-2 (NCT03090659) is an ongoing, Phase 1, single-arm, open-label, first-in-human, study of 74 patients being conducted at four participating hospitals in China evaluating the efficacy and safety of LCAR-B38M CAR-T cells for the treatment of patients with relapsed or refractory multiple myeloma.13

About Multiple Myeloma
Multiple myeloma is an incurable blood cancer that starts in the bone marrow and is characterized by an excessive proliferation of plasma cells.14

Although treatment may result in remission, unfortunately, patients will most likely relapse as there is currently no cure.15 Refractory multiple myeloma is when a patient’s disease is non-responsive or progresses within 60 days of their last therapy.16,17 Relapsed myeloma is when the disease has returned after a period of initial, partial or complete remission and does not meet the definition of being refractory.18 While some patients with multiple myeloma have no symptoms at all, most patients are diagnosed due to symptoms that can include bone problems, low blood counts, calcium elevation, kidney problems or infections.19 Patients who relapse after treatment with standard therapies, including protease inhibitors and immunomodulatory agents, have poor prognoses and few treatment options available.20

Summary of Consolidated Financial Results for the First Three Months of the Fiscal Year Ending March 31, 2021(PDF?433KB)

On August 5, 2020 Sysmex reported that (Press release, Sysmex, AUG 5, 2020, View Source [SID1234563232])

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

1. Results for the First Three Months of the Fiscal Year Ending March 31, 2021

2. Dividend

3. Financial Forecast for the Year Ending March 31, 2021
Our consolidated financial forecast for the fiscal year ending March 31, 2021 is undetermined. Although we are currently investigating the impact of the global novel coronavirus (COVID-19) pandemic on customers’ capital expenditure and demand trends, rationally calculating a financial forecast is problematic at present. We will promptly disclose our financial forecast once calculation becomes possible.

4. Other Information
(1) Changes in significant consolidated subsidiaries (which resulted in changes in scope of consolidation):
No

(2) Changes in accounting policies and accounting estimates
1) Changes in accounting policies required by IFRS: No
2) Other changes in accounting policies: No
3) Changes in accounting estimates: No

(3) Number of outstanding stock (common stock)
1) Number of outstanding stock at the end of each fiscal period (including treasury stock):
209,310,432 shares as of Jun. 30, 2020; 209,266,432 shares as of Mar. 31, 2020
2) Number of treasury stock at the end of each fiscal period:
446,708 shares as of Jun. 30, 2020; 446,680 shares as of Mar. 31, 2020
3) Average number of outstanding stock for each period (cumulative):
208,839,381 shares for the three months ended Jun. 30, 2020
208,723,462 shares for the three months ended Jun. 30, 2019

Note: Quarterly summaries of financial results are excluded from quarterly reviews.
* Explanation regarding the appropriate use of financial forecast and other information
1. Our consolidated financial forecast for the fiscal year ending March 31, 2021 is undetermined.
Although we are currently investigating the impact of the global novel coronavirus (COVID-19) pandemic on customers’ capital expenditure and demand trends, rationally calculating a financial forecast is problematic at present. We will promptly disclose our financial forecast once calculation becomes possible. For details, please refer to "3) Consolidated financial forecast" within "1. Qualitative information on quarterly financial results" on page 5 of the attachment to this
document.

3. Supplementary financial materials (in Japanese and English) will be posted on the Sysmex websit on Wednesday, August 5, 2020.

1. Qualitative information on quarterly financial results
1) Operating performance analysis
Future-related information contained in the text below is based on the judgement as of the end of the fiscal period under review

During the first three months of the fiscal year ending March 31, 2021, in Japan concerns about the spread and prolonged impact of the COVID-19 pandemic are leading to a growing sense of uncertainty about the future, including rapid economic deceleration. Overseas, although economic activity has resumed in China, the COVID-19 pandemic continues to spread. The scale of the global economy is expected to shrink as a result.

On the healthcare front, Japan’s medical and healthcare field is expected to remain robust due to an aging society and increasingly diverse health and medical needs. Looking overseas, the populations of developed countries are aging, while economic growth in emerging markets is causing healthcare demand to increase and prompting higher levels of healthcare quality and service enhancements. These trends are promoting efficient healthcare, with structural changes brought about by artificial intelligence, information and communications technology, and other breaking technologies. However, with the number of COVID-19 cases rising globally, considerations about healthcare systems and public health capable of responding to pandemics like we are currently experiencing are exerting pressure and are likely to cause a major transformation of the healthcare environment itself. Sysmex is also likely to be affected by slowing demand in the short term, with healthcare institutions conducting fewer tests as individual countries introduce measures to prevent
non-essential and non-urgent travel.

Under these conditions, Sysmex launched the CN-6500/CN-3500 automated blood coagulation analyzers in the Japanese market to enhance the workflow efficiency of hemostasis testing. These products offer the same high levels of productivity, reliability, operability, and service as the CN6000/CN-3000 automated blood coagulation analyzers. In addition, they incorporate into a single unit the chemiluminescence enzyme immunoassay (CLEIA) measurement principles used in our HISCL-5000/HISCL-800 automated immunoassay systems. As a result, our new blood
coagulation analyzers allow for flexible measurements in response to a broad range of test orders in the fields of thrombosis and hemostasis, such as molecular markers for blood coagulation measured with CLEIA, in addition to the blood coagulation and platelet aggregation parameters that can be measured by CN-6000/CN-3000 automated blood coagulation analyzers, realizing an efficient testing workflow in a way that caters to needs in healthcare settings. Going forward, we will continue seeking to provide new value by promoting R&D on reagents related to hemostasis and
immunochemistry using CLEIA.

To help the city of Kobe prepare for an increase in infections by strengthening a PCR testing system for COVID-19, the City of Kobe, Sysmex, and SRL, Inc. (a subsidiary of Miraca Holdings Inc. [now H.U. Group Holdings, Inc.]) have configured and begun operating a new PCR testing system at the Sysmex BMA Laboratory, a clinical testing center in the Kobe Biomedical Innovation Cluster. In this initiative, Sysmex will take control of PCR tests. SRL will be in charge of supporting the creation of a testing system, collecting samples and reporting results. We plan to reinforce the PCR testin
implementation system, as necessary. Through this initiative, the three entities aim to reduce the physical and emotional burden of the COVID-19 threat on local residents.

Sysmex also established four antibody measurement technologies that enable detection of the circulating IgG antibody and IgM antibody. These antibodies react specifically to the nucleocapsid protein1 and spike protein2 in SARS-CoV-2, the virus that causes COVID-19. We have begun offering lab assay services using this testing technology for research into the past history of COVID-19 and research and consideration of the clinical significance of the SARS-CoV-2 defense function, as well as in a host of epidemiological studies. Furthermore, we have begun providing a lab assay service for
research on cytokines,3 which have been suggested as a useful indicator in monitoring the risk of increasing severity and treatment effects for SARS-CoV-2. Targeting research institutions, universities, medical institutions and pharmaceutical companies with this assay service, we will provide data that can be used to confirm testing methods suitable to such clinical applications as determining the risk of increasing severity and treatment effect, as well as data that can be used for vaccines, antiviral drugs and other drug discovery research. We aim to contribute to advances in research in amassing broad-ranging clinical evidence, including for epidemiological research, as well
as in drug discovery, to help in the diagnosis and treatment of COVID-19.

1 Nucleocapsid protein (N antigen):
A protein that constitutes the core structure of a virus, significantly affecting virus characteristics.
2 Spike protein (S antigen):
Protein that forms countless protrusions around the virus to bind with cell receptors and generate infection.
3 Cytokine:
This is a general name for proteins secreted by cells and used in intercellular communication.

In Japan, sales of reagents rose in the hematology field, but sales of instruments were down, particularly in the hematology field and in other fields related to laboratory information systems mainly due to the spread of the COVID-19 pandemic. As a result, sales in Japan fell 7.5% year on year, to ¥9,380 million.

Overseas, sales of instruments grew in the urinalysis and life science fields, while reagent sales dropped, centered on the hematology, urinalysis and immunochemistry fields mainly due to the spread of the COVID-19 pandemic. Consequently, overseas sales decreased 12.4% year on year, to ¥51,130 million. The overseas sales ratio fell 0.7 percentage point, to 84.5%.

SG&A expenses fell in all regions mainly due to activity restrictions due to the spread of the COVID-19 pandemic. SG&A expenses were down 8.6% year on year, to ¥18,928 million.

As a result, during the first three months of the fiscal year ending March 31, 2021, the Group recorded consolidated net sales of ¥60,511 million, down 11.7% year on year. Operating profit declined 38.3%, to ¥6,957 million; profit before tax decreased 32.9%, to ¥6,481 million; and profit attributable to owners of the parent fell 33.0%, to ¥4,487 million.

Performance by segment
(1) Japan
In Japan, sales of reagents increased in the hematology field. However, instrument sales declined in the hematology field and in other fields related to laboratory information systems mainly due to the spread of the COVID-19 pandemic. And reagent sales also declined in the immunochemistry field. As a result, segment sale were down 4.1% year on year, to ¥10,513 million.

On the profit front, segment profit (operating profit) fell 10.1%, to ¥6,194 million. The decrease was attributable to lower gross profit, stemming from lower sales and a deteriorating cost of sales ratio, despite lower SG&A and R&D expenses.

(2) Americas
In North America, instrument sales were up in the hemostasis field. However, sales in the region were down due to lower sales of instruments, reagents and maintenance services in the hematology field mainly due to the spread of the COVID-19 pandemic. In Central and South

America, reagent sales fell, mainly in the urinalysis field, but instrument and reagent sales in the hematology field rose, pushing up sales in the region. As a result, overall sales in the Americas were down 12.0% year on year, to ¥12,895 million.

On the profit front, the Americas generated a segment loss (operating loss) of ¥404 million (compared with segment profit of ¥449 million in the first three months of the preceding fiscal year). Profit was affected by lower gross profit, stemming from lower sales and deterioration in the cost of sales ratio, although SG&A expenses fell

(3) EMEA
Sales in the EMEA region declined 6.9% year on year, to ¥18,231 million. Instrument sales rose in the life science field and in other fields in relation to transport systems, but reagent sales were down in the hematology and urinalysis fields mainly due to the spread of the COVID-19 pandemic.

On the profit front, lower sales and deterioration in the cost of sales ratio caused gross profit to decline, while SG&A expenses fell. As a result, segment profit (operating profit) was ¥1,663 million, up 5.9% year on year.

(4) China
In China, sales fell 21.8% year on year, to ¥13,809 million. Instrument sales increased, mainly in the urinalysis and immunochemistry fields, but sales of instruments and reagents were down in the hematology field, as were sales of reagents in the urinalysis and immunochemistry fields mainly due to the spread of the COVID-19 pandemic.

On the profit front, segment profit (operating profit) dropped 84.4%, to ¥287 million as the result of lower gross profit due to falling sales and deterioration of the cost of sales ratio, despite lower SG&A expenses.

(5) Asia Pacific
Instrument sales were up in the hematology field, but regent sales decreased in the hematology and urinalysis fields mainly due to the spread of the COVID-19 pandemic. As a result, sales in the Asia Pacific region decreased 10.7% year on year, to ¥5,062 million.

On the profit front, SG&A expenses decreased, but falling gross profit due to lower sales and deterioration in the cost of sales ratio led to segment profit (operating profit) of ¥284 million, down 53.1% year on year.

2) Financial conditions analysis

(1) Financial conditions
As of June 30, 2020, total assets amounted to ¥368,826 million, down ¥20,465 million from March 31, 2020. As main factors, cash and cash equivalents were down ¥7,857 million, and trade and other receivables (current assets) fell ¥13,906 million, while inventories rose ¥5,128 million.

Meanwhile, total liabilities as of June 30, 2020 were ¥92,523 million, down ¥18,420 million. Principal decreases included trade and other payables, which were down ¥8,075 million; income taxes payable, down ¥3,339 million; accrued bonuses, down ¥2,971 million; and contract liabilities, down ¥2,087 million.

Total equity came to ¥276,302 million, down ¥2,044 million from March 31, 2020. Among principal reasons, retained earnings fell ¥3,030 million, while other components of equity increased ¥517 million. Equity attributable to owners of the parent to total assets rose 3.4 percentage points, from 71.3% on March 31, 2020 to 74.7% on June 30, 2020.

(2) Cash flows
As of June 30, 2020, cash and cash equivalents amounted to ¥48,734 million, down ¥7,857 million from March 31, 2020.
Cash flows from various activities during the first three months of the fiscal year are described in more detail below.

(Cash flows from operating activities)
Net cash provided by operating activities was ¥9,904 million (up ¥2,168 million). As principal factors, profit before tax provided ¥6,481 million (down ¥3,179 million), depreciation and amortization provided ¥6,198 million (up ¥436 million), a decrease in trade receivables provided

¥13,916 million (up ¥9,327 million), an increase in inventories used ¥4,461 million (up ¥823 million), a decrease in trade payables used ¥4,148 million (up ¥2,020 million), and a decrease in consumption taxes receivable provided ¥3,366 million (up ¥424 million).

(Cash flows from investing activities)
Net cash used in investing activities was ¥8,619 million (up ¥8,053 million). Among major factors, purchases of property plant and equipment used ¥1,915 million (down ¥1,342 million), purchases of intangible assets used ¥4,625 million (up ¥2,251 million), payments resulting in an increase in long-term prepaid expenses used ¥1,170 million (up ¥790 million), and proceeds from withdrawal of time deposits decrease ¥7,187 million year on year.

(Cash flows from financing activities)
Net cash used in financing activities was ¥9,085 million (up ¥206 million). This was mainly due to dividends paid of ¥7,517 million (up ¥4 million) and repayment of lease liabilities, which used ¥1,704 million (up ¥263 million).

3) Consolidated financial forecast
Although the COVID-19 pandemic continues to spread around the world, there are signs that economic activity is gradually returning in some countries. Even so, the outlook remains opaque, due to concerns that a second wave could occur and that the impact could be prolonged. Sysmex’s business segment is in the field of healthcare, and over the long term demand in this field is expected to remain high. In the first quarter under review (April to June 2020), demand was down temporarily as the number of hospital tests for items other than COVID-19 decreased, but testing numbers are trending upward. However, the speed of demand recovery differs by country.

Against this backdrop, the degree to which the global COVID-19 pandemic will affect customers’ capital investment and demand trends remains under consideration. As a result, the rational calculation of performance forecasts is problematic at this stage, so our consolidated financial forecast for the fiscal year ending March 31, 2021 remains undetermined. We will promptly discloseour performance forecast once calculation becomes possible.

6) Notes to the condensed quarterly consolidated financial statements
1. Notes related to the going concern assumption
Not applicable
2. Segment information
1) Overview of reportable segments

The Group’s reportable segments are the constituent business units of the Group for which separate financial data are available and that are examined on a regular basis for the purpose of enabling the Managing Board to allocate managerial resources and evaluate results of operations.

The Group is primarily engaged in the manufacture and sale of diagnostic instruments and reagents. These businesses are conducted in Japan by the Company, and in th Americas, EMEA, China and the Asia Pacific by regional headquarters established in those regions. These companies formulate overarching strategies tailored to regional characteristics and conduct business activities accordingly. Regional headquarters and other domestic and overseas subsidiaries are independent management units that handle production and sales for each region.

Accordingly, the Group has five reportable segments comprising geographical segments based on manufacturing and sales systems. These are "Japan," the "Americas," "EMEA," "China," and the "Asia Pacific."

2) Segment profit and operating results
Profit and operating results from continuing operations by reportable segment of the Group are as follows;
Intersegment sales are determined based on market prices or costs of goods manufactured.
Accounting policies of reporting segments are consistent with the Group’s accounting policies indicated in the consolidated financial statements for the previous fiscal year.

1. Segment profit (loss) adjustments of negative ¥78 million include negative ¥132 million for the unrealized gains on inventories and ¥79 million for the unrealized gains on non-current assets.
2. Segment profit (loss) is adjusted to coincide with operating profit in the condensed quarterly consolidated statement of income.

1. Segment profit (loss) adjustments of negative ¥1,068 million include negative ¥1,097 million for the unrealized gains on inventories and ¥110 million for the unrealized gains on non-current assets.
2. Segment profit (loss) is adjusted to coincide with operating profit in the condensed quarterly consolidated statement of income

Allogene Therapeutics Reports Second Quarter 2020 Financial Results

On August 5, 2020 Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T) therapies for cancer, reported financial results for the quarter ended June 30, 2020. (Press release, Allogene, AUG 5, 2020, View Source [SID1234562874])

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"We are incredibly pleased with the progress we’ve made across our AlloCAR T platform, which now includes ongoing clinical trials for ALLO-501, ALLO-501A and ALLO-715," said David Chang, M.D., Ph.D., President, Chief Executive Officer and Co-Founder of Allogene. "The ALLO-501 data we presented at ASCO (Free ASCO Whitepaper) in May solidifies our belief in the potential of AlloCAR T therapy in hematologic malignancies. We look forward to presenting initial data in a second hematologic malignancy, multiple myeloma, later this year as we advance the same innovative approach to solid tumors in 2021."

Recent Highlights

Anti-CD19 AlloCAR T Program
Initial data from ALLO-501’s ALPHA trial provided support for the Company’s approach to AlloCAR T therapy. Allogene intends to leverage ALLO-501 to optimize trial design and dose selection as it prepares for a potentially pivotal Phase 2 trial of ALLO-501A in 2021.

•ALLO-501 ALPHA Phase 1 Trial
In May 2020 at the American Society of Clinical Oncology (ASCO) (Free ASCO Whitepaper) annual meeting, the Company presented initial data from its dose escalation Phase 1 ALPHA study of ALLO-501 in relapsed/refractory non-Hodgkin lymphoma (NHL). This study utilizes ALLO-647, the Company’s anti-CD52 monoclonal antibody (mAb), as a part of its differentiated lymphodepletion regimen. The next readout from this trial is expected to be in late 2020 or early 2021.

As per the ASCO (Free ASCO Whitepaper) presentation, 22 patients were evaluable for safety and 19 patients were evaluable for efficacy with at least one tumor assessment as of the May 2020 data cutoff.
◦Responses were observed across all cell doses and NHL histologies (diffuse large B-cell lymphoma and follicular lymphoma).
◦Across all evaluable patients, there were seven complete responses (CR) and five partial responses (PR) for an overall response rate (ORR) of 63% and CR rate of 37%.
◦In CAR T naïve patients (n=16) the ORR was 75% and the CR rate 44%.
◦Higher dose ALLO-647 was associated with a higher CR rate.
◦With a median follow-up of 3.8 months, nine of the 12 responding patients (75%) remained in response as of the data cutoff on May 11, 2020.
◦No dose limiting toxicities, graft-vs-host disease, or Immune Effector Cell-Associated Neurotoxicity Syndrome (ICANS) was observed. Cytokine release syndrome occurred in 32% of the patients, was mainly mild to moderate

in severity and manageable with standard recommendations. Four patients (18%) experienced serious adverse events (SAE), all of which resolved.

•ALLO-501A ALPHA2 Phase 1 Trial
ALLO-501A is a next generation anti-CD19 AlloCAR T intended for Phase 2 development. During the second quarter, the Company initiated enrollment in the Phase 1 portion of the ALPHA2 trial. This abbreviated dose escalation study is a single-arm, open-label, multicenter trial of ALLO-501A in patients with R/R large B-cell lymphoma. The Company expects to begin the Phase 2 portion of this study in 2021.

Anti-BCMA AlloCAR T Program
The Company continues to progress its robust anti-BCMA strategy centered around ALLO-715 for the treatment of multiple myeloma (MM).

•ALLO-715 UNIVERSAL Phase 1 Trial
◦The ALLO-715 Phase 1 UNIVERSAL trial in patients with relapsed/refractory MM utilizes ALLO-647 as part of the lymphodepletion platform. The initial dose escalation portion of the UNIVERSAL trial using 39mg of ALLO-647 is now complete. The trial continues to enroll patients with initial data anticipated in Q4 2020.
•ALLO-715 + nirogacestat
◦An Investigational New Drug (IND) application is expected to be submitted in the second half of 2020 to evaluate ALLO-715 in combination with SpringWorks’ investigational gamma secretase inhibitor, nirogacestat, in patients with relapsed/refractory MM.
•ALLO-605 (TurboCAR)
◦The Company presented preclinical data on its internally developed TurboCAR technology platform at the American Society of Gene & Cell Therapy (ASGCT) (Free ASGCT Whitepaper) 23rd Annual Meeting in May. TurboCAR technology allows cytokine activation signaling to be engineered selectively into CAR T cells. TurboCAR has the potential to improve efficacy, overcome cell exhaustion, and reduce dosing requirements of AlloCAR T therapy.
◦In 2021, an IND is expected to be submitted for the Company’s first TurboCAR candidate, ALLO-605, an investigational BCMA-directed AlloCAR T therapy for MM.

Solid Tumor AlloCAR T Program
•ALLO-316 (anti-CD70)
◦The Company continues to progress pre-clinical work on ALLO-316, its anti-CD70 AlloCAR T clinical candidate. ALLO-316 has potential application in both hematologic malignancies and solid tumors. The initial focus for this investigational therapy will be renal cell carcinoma with an IND planned by the end of 2020.
Manufacturing Updates
Construction continues on the Company’s state-of-the-art cGMP cell manufacturing facility in Newark, California. The Company continues to expect to initiate cGMP manufacturing from this facility in 2021.

Second Quarter Financial Results
•Research and development expenses were $47.3 million for the second quarter of 2020, which includes $8.0 million of non-cash stock-based compensation expense.
•General and administrative expenses were $15.9 million for the second quarter of 2020, which includes $8.8 million of non-cash stock-based compensation expense.
•Net loss for the second quarter of 2020 was $61.0 million, or $0.53 per share, including non-cash stock-based compensation expense of $16.8 million.
•In June, the Company closed on a secondary offering that raised $632.5 million in gross proceeds prior to deducting underwriting discounts, commissions and offering expenses. This included the exercise in full by the Underwriters of their option to purchase additional shares of common stock. As a result, the Company had $1.1 billion in cash, cash equivalents, and investments as of June 30, 2020.

2020 Financial Guidance
•Allogene continues to expect full year GAAP net losses to be between $260 million and $280 million including estimated non-cash stock-based compensation expense of $70 million to $75 million and excluding any impact from potential business development activities.

Conference Call and Webcast Details
Allogene will host a live conference call and webcast today at 5:30 a.m. Pacific Time / 8:30 a.m. Eastern Time to discuss financial results and provide a business update. To access the live conference call by telephone, please dial 1 (866) 940-5062 (U.S.) or 1 (409) 216-0618 (International). The conference ID number for the live call is 2189084. The webcast will be made available on the Company’s website at www.allogene.com under the Investors tab in the News and Events section. Following the live audio webcast, a replay will be available on the Company’s website for approximately 30 days.

Bicycle Therapeutics to Present at the Canaccord Genuity 40th Annual Growth Conference

On August 5, 2020 Bicycle Therapeutics plc (NASDAQ: BCYC), a biotechnology company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide (Bicycle) technology, reported that management will participate in a fireside chat at the Canaccord Genuity 40th Annual Growth Conference on Wednesday, August 12, 2020 at 8:00 a.m. ET (Press release, Bicycle Therapeutics, AUG 5, 2020, View Source [SID1234562911]). The conference will be held in a virtual meeting format.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

A live webcast of the fireside chat will be accessible in the Investors & Media section of Bicycle’s website at www.bicycletherapeutics.com. An archived replay of the webcast will be available for 90 days following the fireside chat date.